What a Polynucleotide Treatment Figure Covers

A published treatment figure may describe one injection visit, a planned sequence of visits, or a broader package that includes consultation and review. Before comparing two figures, establish the number of sessions, product quantity, injector, areas treated, follow-up, cancellation terms and what happens if treatment is postponed.

Why published treatment figures are not directly comparable

A treatment figure is only useful when its boundaries are clear. One provider may present the amount attached to a single attendance, while another may describe a planned sequence of attendances as one course. Neither format, by itself, tells a reader whether the clinical input, amount of injectable material, number of areas, review arrangements or record keeping are alike.

For polynucleotide injectables, a session can also mean different things operationally. It might include a consultation and injection on the same day. It might instead be an injection appointment following an earlier assessment. A course description may set out intended spacing but leave the final number of sessions dependent on review. A figure published without these distinctions should be treated as incomplete comparison information, not as evidence that two offers are equivalent.

Comparison rule: do not compare the headline figures until each has been converted into the same unit: one named person, one clearly stated treatment area, one stated number of injection visits and one defined set of included services. If a provider cannot state those elements, record the figure as not comparable.

Register status: practical comparison guidance. It is not a claim about effectiveness, safety or clinical suitability.

What a single-session figure should identify

A single-session figure should identify the appointment it buys rather than relying on a treatment name alone. The first question is whether it covers the injectable procedure itself, an initial consultation, or both. A cautious reader should then ask whether a follow-up review is included and whether any assessment needed before injecting is charged or arranged separately.

The treatment area matters. "Face" can be a broad marketing label, whereas the actual plan may concern one limited area or several separately assessed areas. Ask the provider to name the intended area in writing, without assuming that a general label includes every concern discussed at consultation. If more than one area is proposed, ask whether the figure applies to each area, the whole appointment, or a combined plan.

Quantity and product presentation are also relevant to comparison, but they do not by themselves determine appropriateness. The useful question is not whether one number looks larger. It is whether the practitioner can explain what quantity is planned for the stated area, why it is proposed, and whether the plan could change after examination. A fixed published figure may not settle that question.

• Is this figure for an assessment, an injection visit, or both?
• Which anatomical area is included?
• Does it cover one person and one attendance only?
• Is a review appointment included, and when would it occur?
• Will the provider give a written treatment plan before proceeding?

Decision point: a single-session figure is comparable only with another single-session figure where the area, appointment content and planned injection visit are all stated.

What a course figure should identify

A course is a treatment plan, not merely a larger version of one session. Before treating a course figure as a total, ask how many injection visits it includes, the intended interval between them, and whether the sequence is fixed or subject to review. A stated schedule can help a patient organise time, but it should not be mistaken for a guarantee that every person will need, receive or benefit from the same sequence.

Ask what happens when the plan changes. A clinician may decide that an injection should be deferred because of illness, an active skin problem, a new medicine, a reaction after an earlier visit or another clinical consideration. The provider should be able to explain the practical consequence: whether the remaining attendance can be rearranged, whether a review is required first, and how long any arrangement remains valid. This is a contract and consent question as well as an administrative one.

It is also important to distinguish a course that includes a defined number of sessions from an open-ended plan described as a course. The latter may be a discussion of likely scheduling rather than a settled quotation. Write down the wording used. "Two sessions included" is materially clearer than "course recommended", because the first identifies a finite entitlement and the second may not.

A patient should not feel required to commit to later sessions before receiving enough information to consent to the first one. The General Medical Council's guidance on decision making and consent describes consent as an ongoing process, rather than a single event. That principle is relevant where a plan is reviewed over time.

Decision point: compare course figures only after dividing the offer into its named sessions and included reviews. If the session count is not stated, there is no reliable common unit.

Items that may sit outside the headline figure

The most important omitted items are often not optional extras. An initial consultation may be separate from the procedure. A later review may be included, offered only if requested, or treated as another appointment. A provider may require a new assessment if there has been a significant interval, a change in health or a complication. These arrangements should be clear before a person agrees to treatment.

Ask whether the published figure includes the practitioner who will inject, or whether it only describes a clinic service that could be delivered by different people. In the UK, who carries out an injectable procedure matters to consent, accountability and the practical response if a concern arises. The patient should know the injector's name, relevant professional status where applicable, and who will be contactable after the appointment.

Written records are another meaningful part of the service. A sensible record can include the product name, batch details where available, date, treatment area, practitioner, consent discussion and aftercare information. A patient does not need to demand a particular format, but should ask what record will be made and how to obtain a copy. This is especially useful if later care is needed elsewhere.

Decision point: list every excluded element beside the headline figure. An apparently simple comparison is not complete until this list is empty or marked unknown.

Questions about product, quantity and clinical plan

Polynucleotide is a substance class, not a complete description of a procedure. A comparison should therefore separate the proposed product from the appointment structure. Ask for the product's stated name and whether the practitioner will record it in your notes. Ask what amount is intended for the specific area and whether the proposed amount could change after assessment. These are requests for clarity, not instructions about what amount is appropriate.

Do not assume that a treatment figure establishes equivalence between products or between protocols. Different products may have different instructions, presentations and intended uses. The person proposing treatment should explain the basis for their plan in terms a patient can understand, including the limits of the evidence for the outcome being discussed. A published figure cannot substitute for that explanation.

There is a separate question about whether a stated amount is the total amount opened, the amount intended for one area, or the amount spread across several areas. It may be relevant to ask whether unused material would be retained, discarded or never opened in the first place. The answer should be compatible with safe handling and traceable records, rather than framed as a way to extract more from a vial or syringe.

• What is the stated product name?
• What area is the proposed treatment intended to address?
• What quantity is planned for that area, subject to assessment?
• Will the product and batch information be recorded?
• What evidence and uncertainty will be discussed before consent?

Decision point: do not use quantity as a shorthand for value. It is only comparable after the product, area, treatment plan and clinical rationale have been stated.

How to compare two written quotations

Put both quotations into a simple written comparison rather than relying on memory after two consultations. A provider should be willing to clarify their own terms. The aim is not to negotiate a clinical recommendation into a standardised commodity. It is to identify whether the apparent difference is caused by a different number of visits, a different treatment area, separate consultation arrangements, different review arrangements or information that has not yet been provided.

Use the table below after consultation, not as a substitute for it. Marking an item "not stated" is useful information. It signals that further clarification is needed before a decision. Avoid filling gaps with assumptions, especially where a term such as "course", "full face", "review" or "aftercare" has not been defined.

Screenshot rule: choose neither quotation until every field that affects what you will receive is answered or you are content to proceed without it. A lower headline figure may simply describe less, and a broader package may include elements you do not need.

Consent, cancellation and delayed treatment

Published figures should not pressure a person into receiving an injectable procedure before they are ready. Consent should follow a meaningful discussion of the proposed treatment, alternatives, uncertainties, material risks and the individual circumstances that may affect suitability. The General Medical Council states that doctors must support patients to make informed decisions. Where another regulated professional is involved, their professional standards and scope of practice remain relevant.

Ask when payment is expected, what can be cancelled or rearranged, and what happens if the practitioner decides not to inject on the day. The key distinction is between a personal decision to postpone and a clinically driven decision that treatment should not proceed. A clear written answer helps prevent a financial arrangement from undermining a safety decision.

Ask also whether a consultation creates any commitment to a course. It should be clear whether you can take time to consider the information, seek medical advice where appropriate, or decide against treatment. A published offer that cannot be explained without urgency is not made clearer by repeating the figure.

If you have a concern after an appointment, preserve the written quotation, consent material, aftercare instructions and your treatment record. Record the date, symptoms and any contact with the provider. For suspected adverse reactions to medicines or medical devices, the Medicines and Healthcare products Regulatory Agency operates the Yellow Card scheme. Whether a report is appropriate depends on the facts and should not delay urgent medical care.

Decision point: do not treat a booking term as a reason to override new health information, uncertainty or a clinician's decision to defer treatment.

Limits of this comparison guide

This guide explains how to read published treatment figures for polynucleotide injectables. It does not determine whether treatment is suitable, whether a particular product is appropriate, what result someone may experience, or how many sessions any individual should have. Those are clinical questions that require an appropriately qualified practitioner's assessment and an informed consent discussion.

It does not provide a market survey, name providers, compare businesses, give costs, or assess whether a particular quotation is fair. A figure can be clearly described and still be unsuitable for a person's circumstances. Conversely, a more limited figure may be appropriate where only a defined assessment or single appointment is being considered.

This guide also does not set legal requirements for every part of a provider's booking process. Rules and professional obligations may differ according to the practitioner, setting, product classification and the UK nation involved. Readers should not infer that the existence of a published figure proves that a procedure is lawful, clinically indicated or supported by evidence.

It is not emergency advice. Seek urgent medical help for symptoms that may indicate a severe allergic reaction, serious infection, visual disturbance, rapidly worsening pain or other acute concern. Do not wait for an administrative response about a booking or quotation where medical assessment is needed.

Scope: this is a comparison tool for adults considering a proposed polynucleotide injectable procedure in the UK. It does not cover exosome treatments, nor does it provide body-area advertising advice.